Codiak BioSciences, Inc. Common Stock
CDAK
CDAK was delisted on the 4th of April, 2023.
52 hedge funds and large institutions have $260M invested in Codiak BioSciences, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 20 increasing their positions, 9 reducing their positions, and 10 closing their positions.
122% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 9
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
38% more capital invested
Capital invested by funds: $188M → $260M (+$72M)
11% more funds holding
Funds holding: 47 → 52 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APF
Alaska Permanent Fund
Juneau,
Alaska
|
+$12.4M |
| 2 |
BlackRock
New York
|
+$8.56M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.93M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.84M |
| 5 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$2.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.74M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.63M |
| 3 |
CC
Casdin Capital
New York
|
-$1.16M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$902K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$850K |
CDAK Hedge Fund Activity: Q2 2021 in Review
52 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Codiak BioSciences, Inc. Common Stock (CDAK) for Q2 2021, worth a combined $260M — up 38% from $188M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CDAK positions and 10 closed out — a net gain of 5 holders — while 20 added to existing stakes and 9 trimmed.
The largest buyer was Alaska Permanent Fund, adding an estimated $12.4M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $1.74M sold.
- 52 institutional investors held Codiak BioSciences, Inc. Common Stock (CDAK) as of Q2 2021, up from 47 in Q1 2021.
- Funds reported $260M of Codiak BioSciences, Inc. Common Stock stock for Q2 2021, up 38% quarter-over-quarter.
- 15 funds opened new Codiak BioSciences, Inc. Common Stock positions in Q2 2021 and 10 closed out, a net change of +5 holders.
- The largest Codiak BioSciences, Inc. Common Stock buyer in Q2 2021 was Alaska Permanent Fund, an estimated $12.4M added.
- The largest Codiak BioSciences, Inc. Common Stock seller in Q2 2021 was EcoR1 Capital, an estimated $1.74M sold.
Based on aggregated 13F filings for Q2 2021.